Perifosine (also KRX-0401) is a former drug candidate that was under development for a variety of cancer indications.

[2] It was being developed by Keryx Biopharmaceuticals who had licensed it from Æterna Zentaris Inc.[3] In 2010, perifosine received orphan drug status in the U.S. for the treatment of multiple myeloma and neuroblastoma, and for multiple myeloma in the EU.

[5][6] In 2011 it was in a phase III trial for colorectal cancer,[7] and another for multiple myeloma.

[4][8] On April 2, 2012, it was announced that perifosine failed its phase III clinical trial for treatment of colon cancer.

[10] On March 11, 2013 Aeterna Zentaris announced the discontinuing of Phase 3 clinical trial of perifosine for the treatment of relapsed and refractory multiple myeloma.